Compare Bristol-Myers Squibb Co (BMY) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs SMX Security Matters plc — how do they compare? Bristol-Myers Squibb Co trades at $57.42 (market cap $116.30B), while SMX Security Matters plc trades at $17.65 (market cap $17.11M). The key difference: Bristol-Myers Squibb Co is far larger — about 6797.2× SMX Security Matters plc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals.
| BMY | SMX | |
|---|---|---|
Market Cap | $116.30B | $17.11M |
Sector | Health | Technology |
52-Week High | $62.37 | $295.56K |
52-Week Low | $42.60 | $12.87 |
Enterprise Value | $152.24B | $14.08M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SMX trades at $16.21, up 3.58% today, amid neutral technical signals and recent reverse stock splits. The company is positioning itself in the recycling technology space with its Circularity-as-a-Service platform, targeting demand from new state recycling mandates. However, financial metrics show significant challenges with negative ROE of -2,216.26% and ROA of -398.22%, indicating substantial profitability concerns despite a reasonable P/B ratio of 1.93.
The outlook remains speculative with potential upside from regulatory tailwinds in recycling verification technology, but high execution risk given current negative profitability. Investors face substantial dilution risk from recent reverse splits and need to monitor the company's ability to convert regulatory opportunities into sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
